Synthesis, crystal structures and Jack bean urease inhibitory activity of copper(II) complexes with 4-bromo-N′-(2-hydroxy-5-methoxybenzylidene)benzohydrazide

2016 ◽  
Vol 70 (3) ◽  
pp. 544-555 ◽  
Author(s):  
Jing Wang ◽  
Dan Qu ◽  
Jin-Xian Lei ◽  
Zhonglu You
MedChemComm ◽  
2016 ◽  
Vol 7 (5) ◽  
pp. 914-923 ◽  
Author(s):  
Humayun Pervez ◽  
Maqbool Ahmad ◽  
Sumera Zaib ◽  
Muhammad Yaqub ◽  
Muhammad Moazzam Naseer ◽  
...  

The putative binding mode of the most active compound 3b in the active site of Jack bean urease.


2021 ◽  
Vol 68 (4) ◽  
pp. 804-810
Author(s):  
Hui Zhao ◽  
Xiu-Rui Liu ◽  
Xue Wang ◽  
Jing Hu ◽  
Ya-Jun Cai ◽  
...  

A new dinuclear copper(II) complex [Cu2(μ-Br)2L2] · 0.5 MeOH with the benzohydrazone ligand 4-bromo-N’-(1-(pyridin-2-yl)ethylidene)benzohydrazide (HL) has been synthesized and characterized by elemental analysis, IR and UV-Vis spectroscopic studies. Single crystal structures of the complex and the benzohydrazone compound were studied. The Cu atoms in the complex are coordinated by two benzohydrazone ligands and two Br bridging groups, forming square pyramidal coordination. The complex has good inhibitory activity on Jack bean urease, with IC50 value of 1.38 μmol L-1.


2019 ◽  
Vol 19 (29) ◽  
pp. 2658-2675 ◽  
Author(s):  
Ritu Kataria ◽  
Anurag Khatkar

Background: Designing drug candidates against the urease enzyme, which has been found responsible for many pathological disorders in human beings as well as in animals, was done by insilico means. Methods: Studies were carried out on a designed library of diosmin derivatives with the help of Schrodinger’s maestro package of molecular docking software against a crystallographic complex of plant enzyme Jack bean urease (PDB ID: 3LA4). Best twelve derivatives of diosmin were selected for synthesis by considering their interaction energy along with docking score and were further investigated for antioxidant, urease inhibitory and Anti-H. pylori activity by in- vitro method along with ADMET analysis. Results: In-vitro results of series concluded compounds D2a, D2d and D7 (IC50 12.6 ± 0.002, 14.14 ± 0.001 and 15.64 ± 0.012 µM respectively in urease inhibition and 5.195 ± 0.036, 5.39 ± 0.020 and 5.64± 0.005 µM in antioxidant behavior against DPPH) were found to be significantly potent with excellent docking score -11.721, -10.795, -10.188 and binding energy -62.674, -63.352, -56.267 kJ/ mol as compared to standard drugs thiourea and acetohydroxamic acid (-3.459, -3.049 and -21.156 kJ/mol and - 17.454 kJ/mol) whereas compounds D2b, D5b, D5d and D6 were found moderate in urease inhibitory activity. Conclusions: Selected candidates from the outcome of in-vitro urease inhibitory were further examined for anti- H. pylori activity by a well diffusion method against H. pylori bacterium (DSM 4867). Compound D2a showed good anti-H. Pylori activity with a zone of inhibition 10.00 ± 0.00 mm and MIC value 500µg/mL as compared to standard drug acetohydroxamic acid having a zone of inhibition 9.00 ± 0.50mm and MIC 1000µg/mL. In- silico studies played an important role in designing the potent ligands against urease protein as well as in explaining the binding pattern of designed and synthesized ligand within the active pocket of jack bean urease protein. ADMET studies were also carried out to check the drug similarity of designed compounds by the means of quikprop module of molecular docking software. Hence, the present investigation studies will provide a new vision for the discovery of potent agents against H. pylori and urease associated diseases.


Sign in / Sign up

Export Citation Format

Share Document